OCUGEN INC OCGN 深 滬
已收盤 08-07 16:00:00 美东时间
1.28
+0.040
+3.23%
華盛通- 最 高1.30
- 今 開1.26
- 成交量 453.74万股
- 最 低 1.25
- 昨 收 1.24
- 總市值 4.34亿
- 52周最高 2.725
- 市盈率 靜 --
- 換手率 1.34%
- 52周最低 0.98
- 委 比 -36.96%
- 總股本 3.39亿
- 歷史最高 18.77
- 量 比 0.87
- 振 幅 4.03%
- 歷史最低 0.17
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could accelerate OCU410’s regulatory path while further differentiating its one-time treatment for life approa...
07-29 19:13
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
Ocugen, Inc., a biotech leader in gene therapies for blindness, will host a conference call and webcast on August 6, 2026, at 8:30 a.m. ET to discuss its Q2 2026 financial results and provide a business update. A pre-market earnings announcement will also be issued on the same day. Participants can join via dial-in numbers (800) 715-9871 (U.S.) or (646) 307-1963 (international), using conference ID 2222566, or via webcast on Ocugen's investor sit...
07-28 20:01
Cardiff Oncology announces $10M direct offering
Cardiff Oncology (CRDF) announced on Wednesday that it has entered into definitive agreements for the purchase and sale of 8.57M shares of its common stock and accompanying warrants to purchase up to ...
07-15 20:13
Ocugen inks OCU400 licensing deal for MENA
Ocugen ( ($OCGN) ) has shared an announcement. On July 13, 2026, Ocugen announc...
07-14 01:30
Ocugen signs OCU400 licensing term sheet
Ocugen (OCGN) said it signed a binding term sheet to negotiate a licensing agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding for the exclusive rights to its m...
07-13 19:23
Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400
07-13 19:16
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding for exclusive rights to OCU400, a gene therapy for Retinitis Pigmentosa (RP), in the MENA region. Under the agreement, Ocugen will receive up to $4 million in upfront fees and near-term milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen will also manufacture and supply OCU400. RP is a leading cause of inherited vi...
07-13 11:02
Ocugen to Participate in Upcoming July Industry Conferences
Ocugen, Inc., a biotech leader in gene therapies for blindness, announced its participation in July 2026 investor and industry conferences to present its innovative modifier gene therapy platform. Key events include a fireside chat at Piper Sandler Virtual Ophthalmology Day on July 10, 2026, and presentations at the OIS Retina Innovation Summit and ASRS meeting in Montreal. The ASRS sessions will discuss Phase 2 results and safety outcomes of OCU...
07-01 11:00
Rockwell Medical announces 1-for-10 reverse stock split
Rockwell Medical (RMTI) board approved a 1-for-10 reverse stock split, effective July 1, 2026, as the company seeks to regain compliance with Nasdaq. The reverse split, previously authorized by shareh...
06-29 18:59
Definium Therapeutics launches $500M public offering
Definium Therapeutics (DFTX) announced plans for an underwritten public offering of $500M of common shares and, for certain investors, pre-funded warrants. Definium also intends to grant underwriters ...
06-23 04:08
